文献速递产科母胎医学

阿拉伯环托预防宫颈短的双胎妊娠不良围产结局:多中心随机对照试验(PESSARONE)

Arabin pessary to prevent adverse perinatal outcomes in twin pregnancies with a short cervix: a multicenter randomized controlled trial (PESSARONE).
PubMed 文献 · Am J Obstet Gynecol · 2022-02-03

该开放标签多中心随机对照试验纳入宫颈长度<35 mm的双胎妊娠孕妇,在孕16+0至24+0周比较放置阿拉伯环托与单纯标准护理。意向性分析显示不良新生儿结局在环托组为16.8%、对照组为22.5%(风险比0.69,95%置信区间0.39-1.23,P=.210),无显著差异;符合方案分析同样无显著差异,未发现环托相关严重副作用。

要点

  • 宫颈长度<35 mm的双胎妊娠中,阿拉伯环托未显著降低不良新生儿结局(风险比0.69,95%置信区间0.39-1.23,P=.210)。
  • 符合方案分析同样未显示显著差异(风险比0.78,95%置信区间0.47-1.28,P=.320)。
  • 环托使用未伴随严重副作用,早产或自发性早产发生率组间无显著差异。

核心结论

  • 在本研究中,宫颈短的双胎妊娠使用环托并未显著降低不良新生儿结局。

研究设计与样本

  • 开放标签、多中心、随机对照试验,纳入宫颈长度<35 mm的双胎妊娠孕妇,在孕16+0至24+0周随机分组。
  • 共315名孕妇随机接受环托(n=157)或标准管理(n=158)。
  • 主要终点为不良新生儿结局复合指标:围产期或新生儿死亡,或出院前严重新生儿疾病(支气管肺发育不良、III-IV级脑室内出血、脑室周围白质软化、II级及以上坏死性小肠结肠炎、培养证实的脓毒症、需治疗的视网膜病变)。
  • 计划样本量308例妊娠,以确保80%把握度比较至少1名婴儿发生不良新生儿结局的孕妇比例。

主要发现

  • 意向性分析中,不良新生儿结局在环托组为16.8%,对照组为22.5%(风险比0.69,95%置信区间0.39-1.23,P=.210)。
  • 符合方案分析中,两组无显著差异(风险比0.78,95%置信区间0.47-1.28,P=.320)。
  • 早产或自发性早产的发生率组间无显著差异。
  • 未发现与环托使用相关的严重副作用。
  • 10.8%(34名)参与者主要终点数据缺失,其中79%因缺乏父方同意收集新生儿数据。

临床怎么用

  • 原文结论为环托未显著降低不良新生儿结局,未据此给出临床推荐。

局限性

  • 10.8%(34名)参与者主要终点数据缺失,其中79%因缺乏父方同意收集新生儿数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The number of twin pregnancies continues to increase worldwide as both the number of pregnancies obtained by medically assisted reproduction and age at first pregnancy keep rising. Preterm delivery is the major complication associated with twin pregnancies. The effectiveness of preventive treatments such as progesterone or cervical cerclage for women with a short cervix is doubtful in twin pregnancies. The effectivity of cervical pessaries in preventing preterm birth and its associated morbidity and mortality is also controversial. OBJECTIVE: We sought to investigate if the Arabin pessary reduces adverse neonatal outcomes in twin pregnancies with a short cervix. STUDY DESIGN: This open-label, multicenter, randomized controlled trial on twin pregnancies with a cervical length of <35 mm compared pessary placement at 16+0 to 24+0 weeks' gestation with standard care alone. The primary endpoint was a composite of adverse neonatal outcomes, namely peripartum or neonatal death or significant neonatal morbidity before hospital discharge, defined as at least 1 of the following complications: bronchopulmonary dysplasia, intraventricular hemorrhage grade III to IV, periventricular leukomalacia, necrotizing enterocolitis grade II or higher, culture-proven sepsis, and retinopathy requiring treatment. A sample size of 308 pregnancies was planned to ensure 80% power to compare the proportions of women with at least 1 infant with an adverse neonatal outcome. The intention-to-treat analysis after multiple imputation of missing data, was supplemented with a secondary analysis that controlled for gestational age and cervical length, both at inclusion. The primary endpoint was also compared between randomization groups in the per-protocol population, which excluded patients with prespecified major protocol violations (mostly cervical cerclage and/or progesterone after inclusion). Secondary endpoints included preterm birth, spontaneous preterm birth, and pessary side effects. RESULTS: In total, 315 women were randomized to either receive a pessary (n=157) or standard management (n=158). Overall, 10.8% (34 women) of participants had a missing value for the primary endpoint, mostly (79%) because of the lack of paternal consent for neonatal data collection. In the intention-to-treat analysis, the adverse neonatal outcome occurred in 16.8% of the pessary group vs in 22.5% of the control group (risk ratio, 0.69; 95% confidence interval, 0.39-1.23; P=.210). The per-protocol analysis did not show any significant difference between groups (risk ratio, 0.78; 95% confidence interval, 0.47-1.28; P=.320). The occurrence of preterm birth or spontaneous preterm birth did not differ significantly between groups. No serious side effects were associated with pessary use. CONCLUSION: Pessary use in our study did not significantly reduce adverse neonatal outcomes in twin pregnancies with a short cervix.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Groussolles M, Winer N, Sentilhes L, et al. Arabin pessary to prevent adverse perinatal outcomes in twin pregnancies with a short cervix: a multicenter randomized controlled trial (PESSARONE). Am J Obstet Gynecol. 2022. PMID: 35123930. doi:10.1016/j.ajog.2022.01.038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。